ORAOV1 Polyclonal antibody

ORAOV1 Polyclonal Antibody for IP, ELISA
Cat No. 32706-1-AP

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

IP, ELISA

CIAB1, LTO1, Oral cancer-overexpressed protein 1, Protein LTO1 homolog, TAOS1

Formulation:  PBS, Azide, Glycerol
PBS, Azide, Glycerol
Conjugate:  Unconjugated
Unconjugated
Size/Concentration: 

-/ -


ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。


国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター(国内)に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。


保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換/補填対応を承ります。詳細はこちらをご覧ください。


Tested Applications

Positive IP detected inA431 cells

Recommended dilution

ApplicationDilution
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

32706-1-AP targets ORAOV1 in IP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen

CatNo: Ag38523

Product name: Recombinant human ORAOV1 protein

Source: e coli.-derived, PGEX-4T

Tag: GST

Domain: 1-137 aa of NM_153451.2

Sequence: MAGSQDIFDAIVMADERFHGEGYREGYEEGSSLGVMEGRQHGTLHGAKIGSEIGCYQGFAFAWKCLLHSCTTEKDSRKMKVLESLIGMIQKFPYDDPTYDKLHEDLDKIRGKFKQFCSLLNVQPDFKISAEGSGLSF

相同性解析による交差性が予測される生物種
Full Name oral cancer overexpressed 1
Calculated molecular weight15kDa,137aa
Observed molecular weight16 kDa
GenBank accession numberNM_153451.2
Gene Symbol ORAOV1
Gene ID (NCBI) 220064
Conjugate Unconjugated
Form
FormLiquid
Purification MethodAntigen affinity Purification
UNIPROT IDQ8WV07
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

ORAOV1 (oral cancer overexpressed 1) is a candidate proto-oncogene that is frequently amplified and overexpressed in various human squamous cell carcinomas (SCCs), including oral, esophageal, and cervical cancers. In cervical cancer, silencing of ORAOV1 significantly inhibits the growth of HeLa cells by causing S-phase cell cycle arrest and activating apoptosis. Additionally, ORAOV1 is overexpressed in a variety of solid tumors and may promote tumor development by preventing ribosomal damage induced by reactive oxygen species (ROS). Therefore, ORAOV1 is not only an important tumor biomarker but also a potential therapeutic target for multiple cancers.

Protocols

Product Specific Protocols
IP protocol for ORAOV1 antibody 32706-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...
||
New chat

Able

正在加载,请稍候...